Clinical Trial

SYS6090 Combination Therapy in Advanced Lung Cancer

Name: SYS6090 Combination Therapy in Advanced Lung Cancer — clinical trial record (NCT07472647)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.

Trial Details

NCT Number	NCT07472647
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Enrollment	596 participants
Start Date	2026-02-28
Primary Completion	2029-02-28 (estimated)
Study Completion	2030-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-16